SUMMARY We have reviewed recent publications, mostly from 1980 onwards, concerned with the problem of identifying patients with the fragile X chromosome and mental retardation, considering the two practical sides of the problem, that is, identification by their external appearance and by chromosomal studies. We conclude that this condition covers a large range of physical findings which occur in varying degrees in people with the chromosome marker. We have tried to clarify the existent criteria that have to be considered for an accurate cytogenetic diagnosis.
themselves to particular segments of the mentally handicapped population, for instance, those with speech defects5 or macro-orchidism,6 7 and the incidence of cases in these populations may not hold for mental handicap as a whole.
MACRO-ORCHIDISM
Macro-orchidism or testicular enlargement has a well recognised association with the fragile X.6 Association with X linked mental retardation was noted by Escalante et al.8 In 1975 Turner and her colleagues,9 investigating a number of families in New South Wales in a search for a cause for their apparent childlessness, discovered affected males who had bilateral testicular enlargement. Similar findings in mental retardates were noted by Cantu et al'0 and by Ruvalcaba et al.1" Following Sutherland's report citing fragile X in cases of X linked retardation,'2 Turner and her colleagues13 recalled a number of their families with X linked retardation. Of 18 families, they found that eight had macro-orchidism and the fragile X. The other 10 had testes of normal size and lacked the fragile X. Studies since then6 have shown that this association is a very common one, although not invariable. In many of these studies a proportion of males was found to possess the fragile X but not to show testicular enlargement.7 15 [23] [24] [25] Conversely macro-orchidism can also be present without manifestation of the fragile X.
establish. Mattei et a!28 quoted its absence in 15 prepubertal subjects. Prepubertal males included in other studies have been shown to have normal or borderline6 17 20 23 24 or enlarged6 26 testes. The manner of measurement of testicular size is another important variable. Two principal methods are used. The first of these involves measuring testicular width and height with calipers and calculating volume using the formula: V= (length) x (width)2 x rc/6 as described by Cant(u et al. 10 The alternative method is to use a series of ellipsoids of graded size29 comparing them with the palpated size of the testes. The 90th centile of testicular volume is between 23 and 25 ml and this figure has been used as an upper limit for normal 19 of whom were boys. In these, the principal behaviour characteristics were obtained from their parents and teachers and disturbed behaviour was apparently noted in all cases, although this is not elaborated on. Kakhonen et al'7 noticed no specific behaviour problems in their series of 12 males with the marker X. Fitzsimmons et al18 found a cheerful attitude in the four males that they studied with the marker. Herbst et a124 studied a series of patients from families both with and without the marker X and found them generally to be well mannered and pleasant with reasonably good independence skills. Jacobs et al,25 in nine patients with the marker X, described at least three of them as having been hyperactive in childhood. Two had been described as autistic. Almost all were shy initially and four were quite fearful. None became violent. All were friendly when comfortable. Autism was also found in four of 20 cases of fragile X37 and in eight of 30 in another series.38 Hyperactivity, anxiety, mood lability, and autistic features have been described elsewhere.28 39 74 Jacobs et a/23 described most of their 27 cases as happy, out-going, and, in their own way, communicative. Two of the patients studied by Martin and As can be seen from the above commentary, there are no pathognomonic features of the fragile X syndrome. However, running through the various studies are certain main findings, such as mental handicap of some degree, macro-orchidism, a group of facial characteristics, some or all of which may be present, large ears, and behavioural abnormalities.
Therefore, it seems at present that the condition covers a large, but nevertheless circumscribed, range of physical findings which occur in varying degrees in people with the chromosomal marker.
Laboratory diagnosis
The detection of the fragile X in the laboratory is not a routine procedure. Basically it requires the growth of peripheral lymphocytes in a medium with low concentrations of folic acid, like TC 199.42 The picture that emerges in the case of a true positive resembles mosaicism; a proportion of the cells show the fragile X, seldom more than 500% with present techniques. The rest of the cells have a normal X.
The possibility of false positives arises because of our ignorance on two points. Firstly, we do not know if some normal people show the fragile X. Secondly, we do not know if some of the fragile X like chromosomes that are seen in some cells are the genuine product, or some autosome (if only unbanded cells are being studied), or an X chromosome with a gap that appeared for other unknown reasons. The possibility of false negatives arises because it could be difficult to analyse the number of cells required to obtain a high probability of finding a fragile X when it occurs with low frequency, and because we do not know, and therefore cannot control, all the factors that induce the fragile X to express itself in all cells. A third way to find if normal males carry the fragile X or not was proposed by Howard-Peebles,54 and that is to study the brothers of affected males when the mother is a known carrier. This approach is attractive because it is testable. In these families, 50% of the males should have the fragile X and be mentally retarded and 50% should be normal and not have the fragile X, if the hypothesis that the locus for fragile X linked mental retardation is at the fragile site Xq27 is true. In the hypothesis of no association between mental retardation and the presence of the fragile X, half of the non-retarded brothers should have the fragile X, as pointed out by Silverman et al. 55 Unfortunately, there are very few families reported in which all members have been studied both psychologically and cytogenetically, but the data so far support the hypothesis that the locus for mental retardation in this syndrome is at the fragile site. It When is a fragile X a fragile X?
It has been repeatedly observed that under the conditions required to induce the expression of the fragile X, the number of non-specific gaps and breaks occurring in nearly any chromosome in the complement increases.17 23 42 58 Little is known about the frequency with which these non-specific lesions occur and their distribution. In view of the very many reports of mentally retarded patients who also display other characteristics of the fragile X syndrome, and who express the fragile X in less than 4o% of their cells (see for instance Fryns and Van Den Berghe38; 14 out of the 37 males reported showed 4°fragile X or below), it would appear that this lower threshold is too high, particularly for carriers, and its only justification would be in cases where no banding is possible. Herbst et al63 suggest a minimum threshold of expression of I %, and Steinbach et a!581 have shown that, provided that non-specific lesions on the long arm of the X occur with a frequency comparable to the average frequency of such lesions in autosomes, the minimum threshold required for positive confirmation of a carrier is 0 7 % in males and 1 5 % in females. These figures refer to observations made on banded slides from cells grown in TC 199 and are surprisingly similar to the ones found by Mattei et a!59 as the background frequency in the normal population, in banded metaphases, from cells grown in unspecified medium.
A doctor's dilemma
The early 1980s are witnessing a rush to entice the fragile X to express itself reliably in lymphocytes, fibroblasts, amniocytes, or fetal cells. The immediate aims appear to be respectively: to detect patients more accurately and easily, to detect carriers in order to provide them with the required genetic counselling, to detect the fragile X in utero, and, in the case of confirming its presence in the fetus, abortion.
To detect patients more accurately from lymphocytes one could try to increase their 'visibility' by physicochemical means once the slides are made, or the frequency with which the fragile sites express themselves by using biological means while the cells are in culture. On the first line, Zankl and Eberle61 have observed that orcein stained slides in phase contrast improve the 'visibility' of the fragile X. Harrison et a!65 have attributed the reduced frequency with which the fragile X is seen under light microscopy to the low resolving power inherent in that instrument; they were able to see more fragile Xs in the same patient with the scanning electron microscope than with the light microscope. It would appear that its typical aspect might be lost more often in G banded slides. In our experience, R banding gives a clearer picture, but the bromodeoxyuridine used to R band in the FPG or RBG techniques probably reduces the frequency of expression. 6 The effect of 5-fluorodeoxyuridine (0.4 mol/l at the beginning of the culture) in enhancing the frequency of expression was reported simultaneously by Glover67 in America and Tommerup et a!68 in Europe. A month earlier (August 1981) Mattei et a!69 had reported a similar effect with the addition of 10 mg/l methotrexate 24 hours before harvesting. These results reveal some details of the biochemistry involved in the expression of the fragile site; methotrexate inhibits the action of dihydrofolate reductase, and fluorodeoxyuridine inhibits the action of thymidilate synthetase. Both enzymes control the transformation of dUMP to dTMP, one of four bases that constitute DNA, but the exact way in which these contribute to the expression of fragile sites remains obscure. From a practical point of view, they are nevertheless useful because they can induce the expression of fragile X in some patients who otherwise would not have shown it.
The demonstration of the fragile X in fibroblasts was reported by Jacky and Dill in 1980.70 They attributed the higher frequency in fibroblasts to the more gentle harvesting technique and to the use of Na-citrate as hypotonic treatment instead of KCI. They also felt that the degree of chromosome condensation is important in enhancing the frequency, and this was confirmed later by Barbi and Steinbach7l by analysis of prometaphases. Fonatsch72 has remarked that the frequency of metaphases with the fragile X is greater in early passages than in late passages. Like Mattei et a!69 she used MTX and also aminopterine for 24 hours before harvesting, but she used KCI as hypotonic treatment.
Generally speaking, it would appear therefore that the fragile X is expressed in fibroblasts more frequently than in lymphocytes, particularly if the cultures are manipulated in the ways described above. But expression of the fragile X in 1000% of cells has not been achieved yet.
Amniocytes have also been cultured successfully.
The fragile X syndrome: the patients and their chromnosomes The first report came from Jenkins et al73 using methods similar to those described for fibroblasts. Their report was immediately followed by a similar one,76 which also showed the fragile X in lymphocytes from an affected fetus, and by Schmidt et a175 in Europe. These and other authors76 have suggested another component to the problem, that is, genetic heterogeneity in the frequency of expression of the fragile X (some families appear to be easier than others in which to demonstrate the fragile X). Individual consistency in successive cultures has been noticed by Eberle et al.77 All of this brings us now to the doctor's dilemma, which could also be called the unknown quantity for the genetic counsellor. Prospective parents will require to know not only the probability of passing the fragile X to their children, but also the extent to which the children who receive it will be affected. This is a difficult problem since it involves not only the laws governing the transmission of the chromosome, but also those governing its expression, and these are less well understood.
In the case of male descendants, it is clear now that even low frequencies of expression of the fragile X are found in mildly to moderately retarded children, and it would appear that the degree of mental retardation is positively correlated with the frequency of expression of the fragile X,16 but what determines this correlation is still unknown. The expected 1 in 2 risk of a mentally retarded son can be predicted from an obligate carrier mother with reasonable confidence, particularly if there is a history of familial mental retardation, although the degree of mental retardation is at present impossible to predict.
The situation in female descendants is complicated by the fact that they have two X chromosomes in their cells. Very early in the embryonic life of the carrier, one of the two X chromosomes is inactivated in every cell, and it has been suggested that the selection of which one is inactivated is not always random. The number of cells that have an active fragile X and that constitute the nervous system, or those parts of it related to intelligence, might vary from person to person, and this could determine the degree of mental development of the carrier. This might explain the different degrees of intelligence found in obligatory carriers, most of whom are normal, but some of whom are dull or even severely retarded.78 This hypothesis also finds support in recent observations by Howell and McDermott79 and Uchida and Joyce,80 who found that in one severely retarded carrier the proportion of active fragile Xs was 80%, while in two mentally normal carriers the proportion was below 50%. In brief, in the case of female progeny, the prospects are much better since many obligate carriers do not show mental retardation at all. Nevertheless, the possibility of some degree of mental retardation should be left open. It is not possible at present to quantify this risk exactly or to predict the degree of mental retardation.
It would appear to us that in this, as in other situations, Science must steer her course carefully among principles of uncertainty. While studying fetal blood, there appears to be no difficulty in determining the presence of the fragile X, but then, as 1-fecht et a145 have pointed out, "which of the fragile X male fetuses is destined to be retarded (and to what extent), and which is programmed to be of normal intelligence ?". And, conversely, in several cases as we have seen, family studies have pointed towards particular persons, perhaps fresh mutants, as carriers of the fragile X, but then either the corresponding mental retardation, or the fragile X itself, was not expressed.
Before systematic abortion of positive cases becomes the general practice, in spite of our present lack of understanding of the syndrome, we consider that more research should be done in the area of therapy; at least three groups81-83 have reported various degrees of amelioration in patients treated with folic acid. More research will show the type of patient that is likely to benefit most from this treatment, or could confirm the possibility that the fragile X syndrome may be more than one clinical entity, perhaps the heterogeneous result of different mutations of the same gene. This could explain the variability in presentation of this syndrome and in the response to treatment.
